PEOPLE ON THE MOVE
Vectura
James Ward-Lilley, current head of Respiratory, Autoimmune and Inflammatory at AstraZeneca, is leaving the company to lead lung drug company Vectura.
While at AstraZeneca, Ward-Lilley moved from sales and marketing roles in the UK up to country head of Belgium and Luxembourg, and later China and Regional VP for Central Eastern Europe and the Middle East.
This is the second executive loss for AstraZeneca this month, following the departure of Chief Medical Officer Briggs Morrison.
Vectura develops products for airways diseases – a market including asthma and chronic obstructive pulmonary disease, worth an estimated $44bn.
The company has eight products on the market and has disclosed collaborations with Novartis, Sandoz, Baxter, and GSK.
Ward-Lilley replaces Chris Blackwell as CEO.
